Jump to content

User talk:Boatswi

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Welcome!

[edit]

Hello, Boatswi, and welcome to Wikipedia! Thank you for your contributions. I hope you like the place and decide to stay. Here are a few links to pages you might find helpful:

You may also want to take the Wikipedia Adventure, an interactive tour that will help you learn the basics of editing Wikipedia. You can visit The Teahouse to ask questions or seek help.

Please remember to sign your messages on talk pages by typing four tildes (~~~~); this will automatically insert your username and the date. If you need help, check out Wikipedia:Questions, ask me on my talk page, or click here to ask for help on your talk page, and a volunteer should respond shortly. Again, welcome! SwisterTwister talk 21:43, 14 October 2015 (UTC)[reply]

Boatswi, you are invited to the Teahouse!

[edit]
Teahouse logo

Hi Boatswi! Thanks for contributing to Wikipedia. Be our guest at the Teahouse! The Teahouse is a friendly space where new editors can ask questions about contributing to Wikipedia and get help from peers and experienced editors. I hope to see you there! ChamithN (I'm a Teahouse host)

Visit the Teahouse
This message was delivered automatically by your robot friend, HostBot (talk) 17:20, 13 September 2015 (UTC)[reply]

Your submission at Articles for creation: Vincent Cryns (September 19)

[edit]
Your recent article submission to Articles for Creation has been reviewed! Unfortunately, it has not been accepted at this time. The reason left by Onel5969 was:
This submission's references do not adequately show the subject's notability—see the guidelines on the notability of people and the golden rule. Please improve the submission's referencing, so that the information is verifiable, and there is clear evidence of why the subject is notable and worthy of inclusion in an encyclopedia.
What you can do: Add citations (see Wikipedia:Referencing for beginners) to secondary reliable sources that are entirely independent of the subject.
Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit when they have been resolved.
Onel5969 TT me 02:57, 19 September 2015 (UTC)[reply]

Your submission at Articles for creation: Vincent Cryns has been accepted

[edit]
Vincent Cryns, which you submitted to Articles for creation, has been created.
The article has been assessed as Stub-Class, which is recorded on the article's talk page. You may like to take a look at the grading scheme to see how you can improve the article.

You are more than welcome to continue making quality contributions to Wikipedia. Note that because you are a logged-in user, you can create articles yourself, and don't have to post a request. However, you may continue submitting work to Articles for Creation if you prefer.

Thank you for helping improve Wikipedia!

Onel5969 TT me 19:41, 27 September 2015 (UTC)[reply]

Your submission at Articles for creation: Richard Page (Professor) has been accepted

[edit]
Richard Page (Professor), which you submitted to Articles for creation, has been created.
The article has been assessed as Stub-Class, which is recorded on the article's talk page. You may like to take a look at the grading scheme to see how you can improve the article.

You are more than welcome to continue making quality contributions to Wikipedia. Note that because you are a logged-in user, you can create articles yourself, and don't have to post a request. However, you may continue submitting work to Articles for Creation if you prefer.

Thank you for helping improve Wikipedia!

Hermera34 (talk) 15:51, 30 September 2015 (UTC)[reply]

Your submission at Articles for creation: Sanjay Asthana (October 14)

[edit]
Your recent article submission to Articles for Creation has been reviewed! Unfortunately, it has not been accepted at this time. The reason left by SwisterTwister was:
This submission provides insufficient context for those unfamiliar with the subject matter. Please see the guide to writing better articles for information on how to better format your submission.
Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit when they have been resolved.
SwisterTwister talk 21:43, 14 October 2015 (UTC)[reply]

References

[edit]

Thank you for contributing to Wikipedia. Remember that when adding content about health, please only use high-quality reliable sources as references. We typically use review articles, major textbooks and position statements of national or international organizations (There are several kinds of sources that discuss health: here is how the community classifies them and uses them). WP:MEDHOW walks you through editing step by step. A list of resources to help edit health content can be found here. The edit box has a built-in citation tool to easily format references based on the PMID or ISBN. We also provide style advice about the structure and content of medicine-related encyclopedia articles. The welcome page is another good place to learn about editing the encyclopedia. If you have any questions, please feel free to drop me a note. Jytdog (talk) 16:26, 15 October 2017 (UTC)[reply]

Your submission at Articles for creation: Holly Van Remmen (June 19)

[edit]
Your recent article submission to Articles for Creation has been reviewed! Unfortunately, it has not been accepted at this time. The reason left by Asilvering was:
The content of this submission includes material that does not meet Wikipedia's minimum standard for inline citations. Please cite your sources using footnotes. For instructions on how to do this, please see Referencing for beginners. Thank you.
 The comment the reviewer left was:
Can you show sources for the biographical information?
Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit after they have been resolved.
asilvering (talk) 03:49, 19 June 2023 (UTC)[reply]

Your submission at Articles for creation: Holly Van Remmen has been accepted

[edit]
Holly Van Remmen, which you submitted to Articles for creation, has been created.

Congratulations, and thank you for helping expand the scope of Wikipedia! We hope you will continue making quality contributions.

The article has been assessed as Start-Class, which is recorded on its talk page. Most new articles start out as Stub-Class or Start-Class and then attain higher grades as they develop over time. You may like to take a look at the grading scheme to see how you can improve the article.

Since you have made at least 10 edits over more than four days, you can now create articles yourself without posting a request. However, you may continue submitting work to Articles for creation if you prefer.

If you have any questions, you are welcome to ask at the help desk. Once you have made at least 10 edits and had an account for at least four days, you will have the option to create articles yourself without posting a request to Articles for creation.

If you would like to help us improve this process, please consider leaving us some feedback.

Thanks again, and happy editing!

asilvering (talk) 21:39, 25 June 2023 (UTC)[reply]

1000+ refs to isoleu in 2023

[edit]

Your papers are so crucial that they beat out 78,000+ papers published on this amino acid. Ref spamming (similar references) eventually results in those refs being removed. Diverse, high quality review-ish references are recommended. Here are the usually guidelines for established topics (which isoleucine certainly is): WP:SECONDARY and WP:TERTIARY.--Smokefoot (talk) 18:24, 26 November 2023 (UTC)[reply]

thank you for pointing out the importance of secondary and tertiary references for established topics, I was not aware of those guidelines but they make sense. Boatswi (talk) 15:34, 30 November 2023 (UTC)[reply]

Check it out

[edit]

Refs added to mTOR:

June 2016 [1]

20 April 2016 [2][3]

5 March 2016 [4][5][6][7]Cite error: A <ref> tag is missing the closing </ref> (see the help page).[8][9][10][11][12][13]

30 Nov 2015 [14][15]

Oct 18, 2015 [16][17][18][19]

5 March 2015 [20][21]

  1. ^ Kennedy, Brian K.; Lamming, Dudley W. (2016-06-14). "The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging". Cell Metabolism. 23 (6): 990–1003. doi:10.1016/j.cmet.2016.05.009. ISSN 1932-7420. PMC 4910876. PMID 27304501.
  2. ^ Arriola Apelo, Sebastian I.; Pumper, Cassidy P.; Baar, Emma L.; Cummings, Nicole E.; Lamming, Dudley W. (2016-04-18). "Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. doi:10.1093/gerona/glw064. ISSN 1758-535X. PMID 27091134.
  3. ^ Popovich, Irina G.; Anisimov, Vladimir N.; Zabezhinski, Mark A.; Semenchenko, Anna V.; Tyndyk, Margarita L.; Yurova, Maria N.; Blagosklonny, Mikhail V. (2014-05-01). "Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin". Cancer Biology & Therapy. 15 (5): 586–592. doi:10.4161/cbt.28164. ISSN 1555-8576. PMC 4026081. PMID 24556924.
  4. ^ Mitra A, Luna JI, Marusina AI, Merleev A, Kundu-Raychaudhuri S, Fiorentino D, Raychaudhuri SP, Maverakis E (2015). "Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma". J Invest Dermatol. 135 (11): 2873–6. doi:10.1038/jid.2015.252. PMC 4640976. PMID 26134944.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T (Sep 2013). "Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression". Cell Reports. 4 (5): 913–20. doi:10.1016/j.celrep.2013.07.030. PMC 3784301. PMID 23994476.
  6. ^ Nojima A, Yamashita M, Yoshida Y, Shimizu I, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Ishii N, Minamino T (2013-01-01). "Haploinsufficiency of akt1 prolongs the lifespan of mice". PLOS ONE. 8 (7): e69178. doi:10.1371/journal.pone.0069178. PMC 3728301. PMID 23935948.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  7. ^ Baar, Emma L.; Carbajal, Kathryn A.; Ong, Irene M.; Lamming, Dudley W. (2016-02-01). "Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice". Aging Cell. 15 (1): 155–166. doi:10.1111/acel.12425. ISSN 1474-9726. PMC 4717274. PMID 26695882.
  8. ^ Guertin, David A.; Stevens, Deanna M.; Thoreen, Carson C.; Burds, Aurora A.; Kalaany, Nada Y.; Moffat, Jason; Brown, Michael; Fitzgerald, Kevin J.; Sabatini, David M. (2006-12-01). "Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1". Developmental Cell. 11 (6): 859–871. doi:10.1016/j.devcel.2006.10.007. ISSN 1534-5807. PMID 17141160.
  9. ^ Gu, Yanyun; Lindner, Jill; Kumar, Anil; Yuan, Weiping; Magnuson, Mark A. (2011-03-01). "Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size". Diabetes. 60 (3): 827–837. doi:10.2337/db10-1194. ISSN 1939-327X. PMC 3046843. PMID 21266327.
  10. ^ Lamming, Dudley W.; Demirkan, Gokhan; Boylan, Joan M.; Mihaylova, Maria M.; Peng, Tao; Ferreira, Jonathan; Neretti, Nicola; Salomon, Arthur; Sabatini, David M. (2014-01-01). "Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2)". FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 28 (1): 300–315. doi:10.1096/fj.13-237743. ISSN 1530-6860. PMC 3868844. PMID 24072782.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  11. ^ Kumar, Anil; Lawrence, John C.; Jung, Dae Young; Ko, Hwi Jin; Keller, Susanna R.; Kim, Jason K.; Magnuson, Mark A.; Harris, Thurl E. (2010-06-01). "Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism". Diabetes. 59 (6): 1397–1406. doi:10.2337/db09-1061. ISSN 1939-327X. PMC 2874700. PMID 20332342.
  12. ^ Lamming, Dudley W.; Ye, Lan; Katajisto, Pekka; Goncalves, Marcus D.; Saitoh, Maki; Stevens, Deanna M.; Davis, James G.; Salmon, Adam B.; Richardson, Arlan (2012-03-30). "Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity". Science (New York, N.Y.). 335 (6076): 1638–1643. doi:10.1126/science.1215135. ISSN 1095-9203. PMC 3324089. PMID 22461615.
  13. ^ Lamming, Dudley W.; Mihaylova, Maria M.; Katajisto, Pekka; Baar, Emma L.; Yilmaz, Omer H.; Hutchins, Amanda; Gultekin, Yetis; Gaither, Rachel; Sabatini, David M. (2014-10-01). "Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan". Aging Cell. 13 (5): 911–917. doi:10.1111/acel.12256. ISSN 1474-9726. PMC 4172536. PMID 25059582.
  14. ^ Miller, Richard A.; Harrison, David E.; Astle, Clinton M.; Fernandez, Elizabeth; Flurkey, Kevin; Han, Melissa; Javors, Martin A.; Li, Xinna; Nadon, Nancy L. (2014-06-01). "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction". Aging Cell. 13 (3): 468–477. doi:10.1111/acel.12194. ISSN 1474-9726. PMC 4032600. PMID 24341993.
  15. ^ Fok, Wilson C.; Chen, Yidong; Bokov, Alex; Zhang, Yiqiang; Salmon, Adam B.; Diaz, Vivian; Javors, Martin; Wood, William H.; Zhang, Yongqing (2014-01-01). "Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome". PloS One. 9 (1): e83988. doi:10.1371/journal.pone.0083988. ISSN 1932-6203. PMC 3883653. PMID 24409289.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  16. ^ Johnston, Olwyn; Rose, Caren L.; Webster, Angela C.; Gill, John S. (2008-07-01). "Sirolimus is associated with new-onset diabetes in kidney transplant recipients". Journal of the American Society of Nephrology: JASN. 19 (7): 1411–1418. doi:10.1681/ASN.2007111202. ISSN 1533-3450. PMC 2440303. PMID 18385422.
  17. ^ Trelinska, Joanna; Dachowska, Iwona; Kotulska, Katarzyna; Fendler, Wojciech; Jozwiak, Sergiusz; Mlynarski, Wojciech (2015-04-01). "Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening". Anti-Cancer Drugs. 26 (4): 437–442. doi:10.1097/CAD.0000000000000207. ISSN 1473-5741. PMID 25719621.
  18. ^ Lamming, Dudley W.; Ye, Lan; Astle, Clinton M.; Baur, Joseph A.; Sabatini, David M.; Harrison, David E. (2013-08-01). "Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive". Aging Cell. 12 (4): 712–718. doi:10.1111/acel.12097. ISSN 1474-9726. PMC 3727050. PMID 23648089.
  19. ^ Arriola Apelo, Sebastian I.; Neuman, Joshua C.; Baar, Emma L.; Syed, Faizan A.; Cummings, Nicole E.; Brar, Harpreet K.; Pumper, Cassidy P.; Kimple, Michelle E.; Lamming, Dudley W. (2015-10-13). "Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system". Aging Cell. doi:10.1111/acel.12405. ISSN 1474-9726. PMID 26463117.
  20. ^ Baar, Emma L.; Carbajal, Kathryn A.; Ong, Irene M.; Lamming, Dudley W. (2016-02-01). "Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice". Aging Cell. 15 (1): 155–166. doi:10.1111/acel.12425. ISSN 1474-9726. PMC 4717274. PMID 26695882.
  21. ^ Caron, Alexandre; Richard, Denis; Laplante, Mathieu (2015-01-01). "The Roles of mTOR Complexes in Lipid Metabolism". Annual Review of Nutrition. 35: 321–348. doi:10.1146/annurev-nutr-071714-034355. ISSN 1545-4312. PMID 26185979.

--Smokefoot (talk) 20:14, 26 November 2023 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=User_talk:Boatswi&oldid=1187647064"